Moreover, a therapy targeting both CD47 and VEGF, along with the administration of a bispecific fusion protein SIRPα-VEGFR1, achieved remarkable enhancements in the TIME and a substantial augmentation of the anti-tumor response, suggesting the substantial benefit of combining anti-CD47 therapy with anti-angiogenic treatment for combatting GC [191]. This evidence concerns the gene SIRPA and gastric cancer.